safety-lane.com 07105
chiropractic-lane.com
www.shopcbd-lane
NEWARK
http://www.healthy-lane.com/
Insomnia Med Tied to Lower Alzheimer’s Pathology
An insomnia medication has been linked to lower levels of Alzheimer’s disease (AD) pathology in humans, results of a small proof-of-concept study show.
A 20-milligram dose of suvorexant (Belsomra, Merck) over a 2-night period was associated with a 10%-20% drop in amyloid-beta (Aβ) levels and a 10%-15% reduction in hyperphosphorylated tau in a group of cognitively healthy individuals.
The US Food and Drug Administration (FDA) approved suvorexant, a dual orexin receptor antagonist, a Schedule IV controlled substance, in 2014, and it was first marketed in 2015.
Senior author Brendan Lucey, MD, associate professor of neurology and director of Washington University’s Sleep Medicine Center in St Louis, Missouri, told reporters attending a press briefing that the study is exciting, in part because suvorexant has a long history of proven safety.
“Although it’s a controlled substance, in contrast to some other drugs that have been investigated as potential Alzheimer’s disease-modifying drugs and interventions, the safety profile is already well known,” Lucey said in a briefing with reporters.
The findings were published online April 20, 2023, in Annals of Neurology.
However, Lucey cautioned against reading too much into this small trial.
“This is really a proof-of-concept study, and it does not support going out and taking suvorexant to prevent or delay Alzheimer’s disease,” he said.
Ann Neurol. Published online March 10, 2023. Abstract
via Blogger https://bit.ly/41MBdD6
Recent Comments